ONO-4685-04:ONO-4685 Phase 1 study Single intravenous continuous infusion and subcutaneous administration study in Japanese healthy adult male subjects
Latest Information Update: 05 Dec 2025
At a glance
- Drugs Besufetamig (Primary) ; Besufetamig (Primary)
- Indications Autoimmune disorders; Chronic lymphocytic leukaemia; T-cell lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Ono Pharmaceutical
Most Recent Events
- 05 Dec 2025 New trial record